Maria Rosario Capeding

Maria Rosario Capeding

Auto-generated profile, based on publicly available information

Maria Rosario Capeding

Asian Hospital and Medical Center, Muntinlupa City, Metro Manila, Philippines

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2024 in Vaccine
Verified
Journal Article
Closed access
BQBeatriz Puzon Quiambao
Beatriz Puzon Quiambao
RPRonald Allan Payumo
Ronald Allan Payumo
CRCamilo Roa
Camilo Roa
CBCharissa Fay Borja-Tabora
Charissa Fay Borja-Tabora
MMMay Emmeline Montellano
May Emmeline Montellano
JMJ. Bruce McClain
J. Bruce McClain

27 January 2022 in npj Vaccines
Verified
Journal Article
Open access
PDF file
MCMaria Rosario Capeding
Maria Rosario Capeding
BTBirkneh Tilahun Tadesse
Birkneh Tilahun Tadesse
ASArijit Sil
Arijit Sil
EAEdison Alberto
Edison Alberto
DKDeok Ryun Kim
Deok Ryun Kim
SSSushant Sahastrabuddhe
Sushant Sahastrabuddhe
Vaccination with typhoid conjugate vaccines (TCV) is a major part of typhoid prevention. However, little is known about long-term immune persistence following vaccination with TCVs. In this phase-2, randomized double-blind trial (NCT03527355), 285 children aged 6–23 months were randomized to one of three groups: (1) the group that received a first dose of Vi polysaccharide conjugated to diphtheria-toxoid (Vi-DT) vaccine followed by an “early booster” at 24 weeks, (2) the group that which received a first dose of Vi-DT followed by a “late booster” at 96 or 110 weeks, and (3) comparator group. Safety and immunogenicity of anti-Vi IgG GMTs were assessed at weeks 0, 4, 24, 28, 60, 96, 110, and 114 since the first dose. Here, we describe persistence of immune responses at weeks 60, 96, 110, and 114 post first dose. The anti-Vi IgG seroconversion rate after 27.5 months of follow-up was 88.16% (95% CI: 79.00, 93.64) in late-booster and 94.76% (95% CI: 86.91, 97.88) in early booster Vi-DT groups (p = 0.081). Whereas anti-Vi IgG GMTs were significantly higher in the early booster group (11.95 [95% CI: 9.65, 14.81]) than prebooster GMTs in the late booster group (5.50 [95% CI: 4.44, 6.80], p < 0.0001). GMT in the late booster group significantly increased to 351.76 (95% CI: 265.01, 466.93) (p < 0.0001) when measured 4 weeks after they received their “late-booster” shot. In conclusion, late booster dosing with Vi-DT at 27.5 months post first dose was safe and elicited robust anti-Vi IgG immune responses. Anti-Vi IgG seroconversion rates were persistently comparable in early and late-booster Vi-DT groups.

1 January 2024 in Clinical and Experimental Vaccine Research
Verified
Journal Article
Open access
PDF file
RLRenan James Lim
Renan James Lim
XQXiangyan Qiu
Xiangyan Qiu
EAEdison Alberto
Edison Alberto
MCMaria Rosario Capeding
Maria Rosario Capeding
JCJosefina Carlos
Josefina Carlos
ZMZenaida Mojares
Zenaida Mojares
Lim RJ, et al. Clin Exp Vaccine Res. 2024 Oct;13(4):329-337. https://doi.org/10.7774/cevr.2024.13.4.329

1 October 2021 in Asian Biomedicine
Verified
Journal Article
Open access
PDF file
MCMaria Rosario Capeding
Maria Rosario Capeding
MBMelanie de Boer
Melanie de Boer
SDSilvia Damaso
Silvia Damaso
AGAdrienne Guignard
Adrienne Guignard
Background: The incidence of dengue is increasing rapidly and is a challenging health issue in the Philippines. Epidemiological data are largely based on a passive-surveillance reporting system, which leads to substantial under-reporting of cases. Objectives: To estimate dengue infection and disease incidence prospectively at the community level in an endemic area of the Philippines using an active surveillance strategy. Methods: We implemented active surveillance in the highly endemic community of Alaminos, Laguna. The study consisted of a 1-year follow-up with 2 visits scheduled at the start and end of the study, as well as regular active surveillance in between and unscheduled visits for suspected cases. Blood samples were collected and analyzed to detect dengue during the first scheduled visit and all unscheduled visits, and clinical examination was performed at all visits (registered at clinicaltrials.gov NCT02766088). Results: We enrolled 500 participants, aged from 6 months to 50 years; 76.2% were found positive for immunoglobulin G (95% confidence interval [CI], 71.9–80.0), with 92.0% among those aged 9–17 years. Active (weekly) surveillance identified 4 virologically confirmed cases of dengue (incidence proportion 0.8; 95% CI 0.3–2.1); all in participants aged ≤14 years. Conclusions: Routine surveillance programs such as sentinel sites are needed to characterize the entire clinical spectrum of symptomatic dengue, disease incidence, and transmission in the community.

23 February 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
GLGippeum Lim
Gippeum Lim
JPJuyeon Park
Juyeon Park
YCYun Jung Chang
Yun Jung Chang
SOSera Oh
Sera Oh
HPHyeong Cheol Park
Hyeong Cheol Park
JYJae Seung Yang
Jae Seung Yang
Background: Typhoid conjugate vaccines (TCVs) are increasingly recommended for use in endemic regions, particularly among young children. Despite their growing implementation, the qualitative features of TCV-induced antibody responses, and how these vary by age and immune background, remain incompletely defined.Methods: A systems serology approach was used to comprehensively profile the biophysical and functional characteristics of antibody responses elicited by Vi-diphtheria toxoid conjugate (Vi-DT) and Vi polysaccharide (Vi-PS) vaccines in a phase 1 clinical trial. Participants were stratified by age (children vs adults) and baseline anti-Vi IgG serostatus (seronegative vs seropositive). Multivariate analyses delineated immune signatures associated with vaccine formulation, age, and baseline immunity.Findings: Vi-DT induced significantly higher magnitude and functional quality of antibody responses than Vi-PS across all subgroups. Among Vi-DT recipients, distinct immune profiles were defined by age and serostatus. Children and seronegative individuals showed enrichment of IgG3, enhanced antibody-dependent cellular phagocytosis (ADCP), neutrophil phagocytosis (ADNP), and complement deposition (ADCD)—features linked to early innate activation. By contrast, adults and seropositive individuals displayed enrichment of IgG2, IgG4, IgA2, and Fcα receptor binding, reflecting an antigen-experienced (memory) profile. Booster dosing of Vi-DT in children further enhanced Fcγ receptor binding and ADNP activity, identified as correlate of protection in typhoid controlled human infection model (CHIM), supporting the consideration of booster dose in children.Interpretation: Vi-DT elicits robust and qualitatively distinct antibody responses across immunological backgrounds, characterised by systemic and potential mucosal immune activation. These data provide insight into the superior efficacy of Vi-DT, particularly in young or immunologically naïve individuals, and support booster strategies to strengthen functional antibody responses.